![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, August 24, 2011 11:11:11 PM
Published on Wednesday, 24 August 2011 00:00 Written by Liz Highleyman
HIV and HCV © Russell Kightley
One-third of HIV positive men who have sex with men (MSM) who were treated for acute hepatitis C virus (HCV) infection in Amsterdam became re-infected within 2 years, indicating a need for improved prevention efforts, according to a recent report.
Femke Lambers from the Amsterdam Public Health Service and colleagues with the MOSAIC (MSM Observational Study of Acute Infection with Hepatitis C) study group assessed the incidence of re-infection among HIV positive gay and bisexual who cleared HCV following treatment of acute primary (first case) hepatitis C. They presented their findings at the 18th Conference on Retroviruses and Opportunistic Infection (CROI 2011) and in the August 19, 2011, advance online edition of AIDS.
Starting around the year 2000, clinicians began reporting cases of apparently sexually transmitted acute HCV infection among HIV positive gay and bisexual men, first in the U.K. and then in major cities in Europe, Australia, and the U.S.
Overall, HIV positive people are more likely to develop chronic HCV infection (that is, they are less likely to clear spontaneously without treatment), experience more rapid liver disease progression, and do not respond as well to interferon-based therapy as people with HCV alone; treatment is considerably more effective, however, if started during acute infection. Unlike many diseases, HCV infection does not confer immunity and people can become infected multiple times.
The researchers analyzed 56 HIV positive MSM at 2 large HIV outpatient clinics in Amsterdam who were previously diagnosed with presumed sexually transmitted acute HCV infection, were treated between 2003 and 2011, and had undetectable HCV RNA at the end of therapy.
HCV re-infection was defined as detectable HCV viral load with a switch in HCV genotype or clade, indicating new infection rather than potential late post-treatment relapse. This method would not count men who were infected a second time with the same type of HCV, thus possibly underestimating the re-infection rate.
Results
From 2006 through 2009, 5 of the 56 participants experienced presumed HCV relapse and were not included in further analysis.
11 of the remaining 51 participants were found to be re-infected with a different type of HCV during a median follow-up period of 1.3 years.
The median time until re-infection was 8.4 months.
The incidence of HCV re-infection in this group was 15.2 per 100 person-years.
The cumulative incidence of re-infection was 33% within 2 years.
Most men switched from HCV genotype 4 to genotype 1.
3 men were re-infected with the same genotype but a different clade.
CD4 counts did not differ between participants with and without HCV re-infection, and all re-infected patients on antiretroviral therapy had undetectable HIV viral load.
Among 21 men with available data on behavior, those who were re-infected were significantly more likely to report non-injection recreational drug use, but no statistically significant differences in sexual activity were observed in this small population.
4 re-infected men were treated a second time: 2 achieved sustained virologic response (SVR), 1 relapsed, and 1 was still undergoing follow-up at the time of the report.
"An alarmingly high incidence of HCV re-infection was found in this group," the study authors concluded. "This high re-infection rate indicates that current prevention measures should be discussed, frequent HCV RNA testing should be continued after successful treatment and in case of possible relapse, clade typing should be performed to exclude re-infection."
Given the lack of association between CD4 T-cell count and re-infection, they recommended that more research is needed of the relationship between HIV infection and acquisition of HCV.
Most importantly, they elaborated in their discussion, "these findings stress the importance of repeated risk counseling for HCV transmission, which should be provided not only before and during treatment but also after its completion."
Investigator affiliations: Department of Research, Cluster infectious diseases, Public Health Service of Amsterdam, Netherlands; Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, CINIMA, Academic Medical Center, Amsterdam, Netherlands; Department of Medical Microbiology, Section of Clinical Virology, Academic Medical Center, Amsterdam, Netherlands; Department of Microbiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.
8/23/11
Reference
FAE Lambers, M Prins, X Thomas, et al on behalf of the MOSAIC (MSM Observational Study of Acute Infection with hepatitis C) study group. Alarming incidence of hepatitis C virus (HCV) reinfection after treatment of sexually acquired acute HCV infection in HIV-infected men having sex with men in Amsterdam. AIDS (abstract). August 19, 2011 (Epub ahead of print).
Recent AEMD News
- Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update • PR Newswire (US) • 06/27/2024 08:15:00 PM
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024 • PR Newswire (US) • 06/21/2024 12:01:00 PM
- Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 06/18/2024 12:01:00 PM
- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies • PR Newswire (US) • 06/03/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 05:24:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:05:28 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/17/2024 04:15:21 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/16/2024 08:05:23 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/15/2024 01:27:15 PM
- Aethlon Medical Announces Pricing of $4.7 Million Public Offering • PR Newswire (US) • 05/15/2024 01:15:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/13/2024 09:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 12:01:40 PM
- Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma • PR Newswire (US) • 05/10/2024 12:01:00 PM
- Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices • PR Newswire (US) • 02/21/2024 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 10:15:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:41 PM
- Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 02/14/2024 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024 • PR Newswire (US) • 02/07/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:06:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:04:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:02:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:01:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 12:49:31 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM